## APH PE Stream Chart Analysis **Current Valuation (Latest Data Point):** As of the latest data point (mid-March 2026), APH's monthly average price stands at approximately **$127.81**, which places it in the **"Fair" (合理)** valuation zone — trading above the 25.9x PE boundary (priced at ~$90.97) but below the 30.4x PE boundary (priced at ~$106.43). Wait — re-examining the boundaries: at the latest date, PE_stream_3 (30.4x) = $106.43, PE_stream_4 (34.8x) = $121.85, and PE_stream_5 (39.2x) = $137.31. With a price of $127.81, APH is currently trading **between the 34.8x and 39.2x PE boundaries**, placing it in the **"Overvalued" (高估) zone**. This means the stock is priced above the 34.8x PE upper boundary (~$121.85) but remains below the 39.2x boundary (~$137.31), suggesting elevated but not extreme valuation relative to its historical PE range of 21.6x–43.6x. **Historical Valuation Trend:** From early 2021 through mid-2023, APH traded predominantly in the **"Undervalued" to "Value"** zones, with monthly average prices consistently ranging between $30 and $43 — well below even the lowest PE boundary of 21.6x (which itself ranged from ~$21.76 to ~$34.83 during that period). This indicated the stock was attractively priced relative to earnings throughout that stretch. A meaningful inflection point emerged in late 2023 and accelerated through 2024, as prices climbed from ~$47 to over $71, pushing APH progressively through the **"Fair" (30.4x)** and into the **"Watch" (34.8x)** zones. The PE stream boundaries themselves expanded steadily upward — reflecting consistent earnings growth — which kept the river chart trending upward throughout the entire observation period, a positive signal of improving profitability. The most dramatic valuation re-rating occurred from mid-2025 onward, when the stock surged from ~$84 to a peak of ~$147 in early 2026, briefly touching the **"Warning" (43.6x)** zone before pulling back to the current "Overvalued" range. Overall, APH's valuation has expanded significantly from deeply undervalued territory in 2021–2023 to an elevated "Overvalued" positioning today, warranting cautious monitoring despite the company's clearly upward-trending earnings trajectory.